Abstract 3900: Tegavivint, a first-in-class TBL1 inhibitor demonstrates potent activity in WNT-driven colorectal cancers.
Raffaella Soldi(Banner Health), Sunil Sharma(Banner Health), Julissa Simmons(Io Therapeutics (United States)), Stephen Horrigan(Translational Genomics Research Institute), Jaeger Moore(Banner Health), Tithi Ghosh Halder(Banner Health), Serina Ng(Banner Health), Jamie Cox(HonorHealth), Mahtab Youseffi(Io Therapeutics (United States)), Aundrietta D. Duncan(Io Therapeutics (United States)), Elena Ramirez(Io Therapeutics (United States)), Taylor Bargenquast(HonorHealth)
Cited by 0
Related Papers
TRIM24 Is a p53-Induced E3-Ubiquitin Ligase That Undergoes ATM-Mediated Phosphorylation and Autodegradation during DNA Damage
|Molecular and Cellular Biology|2014|106
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer
|Nature Communications|2021|43
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children
|European Journal of Cancer|2020|25